Topics

STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia

11:52 EST 7 Nov 2019 | STAT

Arkuda has developed several experimental drugs for the disease, GRN-related frontotemporal dementia (or FTD-GRN).

Original Article: STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia"

Quick Search